Paraoxonase enzyme activity is enhanced by zinc supplementation in hemodialysis patients.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

This study was designed to evaluate the effects of zinc supplementation on paraoxonase (PON) enzyme activity in patients on HD.

Who Took Part

PubMed indexes the participants as middle-aged adults, both men and women.

Sixty HD patients were enrolled and divided into two groups: treatment (case) and control.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

This double-blind randomized controlled trial was conducted from June 2005 to June 2007.

Serum zinc concentration was measured by atomic absorption spectrophotometry.

PON activity was evaluated by spectrophotometric method.

Lipid profile was determined using commercial kits, and apolipoprotein AI (Apo-AI) and B (Apo-B) levels were measured by commercial immunoturbidimetric kits.

What Was Measured

Topics PubMed links to this paper include Apolipoproteins B, Aryldialkylphosphatase, Atherosclerosis, Biomarkers, Cholesterol, Dietary Supplements and Kidney Failure, Chronic.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2012 (Renal failure), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.